-
Lose weight while gaining weight! Novo Nordisk plans to acquire hypertension treatment drugs for $1.3 billion
Novo Nordisk, which relies on the GLP-1 weight loss pill, is aggressively acquiring its product pipeline to gain weight. On October 16th local time, the Danish pharmaceutical giant Novo Nordisk annou ... -
Moderna's first mRNA drug factory in China starts construction
On November 28, Moderna, a manufacturer of COVID-19 vaccine, said that the company started to build its first mRNA drug production plant in China this month. It is understood that the COVID-19 vaccin ... -
Novo Nordisk seeks to develop obesity prevention drugs
On December 5th, Novo Nordisk is conducting experiments and research to understand the causes of obesity and seeking to develop drugs to prevent obesity. -
Novo Nord welcomes good news again! Wegovy's drug adherence is much higher than that of regular weight loss drugs
According to analysis of medical records and insurance claims data in the United States, 40% of patients who took the Novo Nordisk weight loss medication Wegovy between 2021 and 2022 continued to tak ... -
Zaiding Medicine: Wei Weijia (Agamod) α Injection has been included in the national medical insurance drug catalog
Zaiding Pharmaceutical announced on December 13th that Wei Weijia& Reg; (Agamod) α Injection (Wei Weijia) has been included in the 2023 National Basic Medical Insurance, Work Injury Insurance, and M ... -
Bristol Myers Squibb announces acquisition of schizophrenia drug manufacturer Karuna for $14 billion
On December 22nd local time, Bristol Myers Squibb and Karuna Therapeutics announced that they had signed a final merger agreement. According to the agreement, Bristol Myers Squibb has agreed to acqui ... -
Sanofi lipid-lowering drug Zhilida approved in China
On December 27th, Sanofi announced on its official WeChat account that its rosuvastatin ezetimibe tablets (I) have been approved by the National Medical Products Administration of China for the treat ... -
Musk responded to "drug use" by conducting a three-year randomized drug test in accordance with NASA's requirements
Recently, the Wall Street Journal of the United States revealed that Tesla and SpaceX CEO Elon Musk frequently used drugs, which raised concerns about the company's operations. In response, Musk pers ... -
Weight loss pills will bring benefits again! FDA assessment: Wegovy and other drugs are not associated with suicidal thoughts
The latest discovery by US regulatory agencies that GLP-1 weight loss drugs such as Wegovy under Novo Nordisk are not associated with suicidal thoughts is a positive signal for these popular drugs an ... -
Nearly 800 drugs in the United States collectively raise prices. Novo Nordisk's "weight loss miracle drug" has risen by 3.5%
Novo Nordisk and Lilly's GLP-1 diabetes drug prices were raised in the United States. On January 18, local time, it was reported that many pharmaceutical enterprises had increased the sales prices of ... -
Lilly plans to launch the obesity drug Telposide in India as early as next year
On February 28th, Eli Lilly CEO Dai Wenrui stated in an interview that the company expects to launch the obesity drug Tirzepatide in India as early as next year. During his keynote speech at the BioA ... -
Merck focuses on the development of next-generation cardiac metabolic drugs and competes with oral weight loss therapies
On June 11th, Robert Davis, CEO of pharmaceutical giant Merck, stated at Goldman Sachs Global Healthcare Conference that the company will focus on developing second-generation and third-generation ca ... -
Apple's new patent explores the future of Vision Pro headset: relieving pain for people with disabilities and helping them reduce drug dependence
According to the latest list published by the US Patent and Trademark Office (USPTO), Apple has obtained a patent related to the Vision Pro headset, which describes the use of mixed reality technolog ... -
GlaxoSmithKline agrees to pay up to $2.2 billion to resolve approximately 80000 lawsuits related to the heartburn drug Zantac
GlaxoSmithKline announced on October 9th that it has reached agreements with 10 plaintiff companies, representing a total of 93% (approximately 80000 cases) of the pending lawsuit against GlaxoSmithK ... -
GlaxoSmithKline agrees to pay up to $2.2 billion to resolve approximately 80000 lawsuits related to the heartburn drug Zantac
According to Interface News, GlaxoSmithKline announced on October 9th that it has reached agreements with 10 plaintiff companies, representing a total of 93% (approximately 80000 cases) of the pendin ...